Valuation: Sernova

Market Cap 4.15Cr 2.91Cr 2.59Cr 2.42Cr 2.2Cr 280.14Cr 4.19Cr 29Cr 11Cr 143.21Cr 11Cr 11Cr 459.61Cr P/E 2026 *
-4.2x
P/E 2027 * -3.5x
Enterprise Value 4.15Cr 2.91Cr 2.59Cr 2.42Cr 2.2Cr 280.14Cr 4.19Cr 29Cr 11Cr 143.21Cr 11Cr 11Cr 459.61Cr EV / Sales 2026 *
-
EV / Sales 2027 * 16.6x
Free-Float
89.49%
Yield 2026 *
-
Yield 2027 * -
1 week+16.67%
1 month-8.70%
3 months-19.23%
6 months-30.00%
Current year-19.23%
1 week 0.08
Extreme 0.085
0.12
1 month 0.08
Extreme 0.085
0.15
3 years 0.08
Extreme 0.085
0.82
5 years 0.08
Extreme 0.085
2.22
10 years 0.08
Extreme 0.085
2.87
Manager TitleAgeSince
Chief Executive Officer 58 12/08/2024
Director of Finance/CFO 60 11/10/2024
Investor Relations Contact - 11/10/2024
Director TitleAgeSince
Director/Board Member 60 19/04/2012
Director/Board Member - 24/04/2023
Director/Board Member - 01/09/2024
Change 5-day change 1-year change 3-year change Capi.($)
-4.55%+22.22%-41.67%-86.36% 2.92Cr
+0.84%-3.53%-26.95%+0.67% 17TCr
-0.07%-2.41%-8.89%+10.23% 11TCr
+0.90%+2.11%-24.36%+0.79% 10TCr
-1.24%-1.31%-48.43%-13.54% 7.48TCr
-0.24%-0.26%-0.87%+71.72% 5.91TCr
-0.86%+4.49%+17.49%+57.78% 5.18TCr
-0.71%-1.36%-7.41%-31.61% 4.85TCr
+0.12%+0.97%-16.40%+18.55% 4.08TCr
-1.01%-2.41%+29.18%-8.51% 3.25TCr
Average -0.25%-0.16%-12.83%+1.97% 7.67TCr
Weighted average by Cap. +0.02%-0.91%-15.78%+9.40%

Financials

2026 *2027 *
Net sales - 25L 17.54L 15.58L 14.54L 13.26L 17Cr 25.23L 1.76Cr 68.2L 8.62Cr 65.84L 64.41L 28Cr
Net income -1.13Cr -79.27L -70.43L -65.74L -59.92L -76Cr -1.14Cr -7.96Cr -3.08Cr -39Cr -2.98Cr -2.91Cr -125.02Cr -1.39Cr -97.51L -86.64L -80.86L -73.7L -94Cr -1.4Cr -9.79Cr -3.79Cr -48Cr -3.66Cr -3.58Cr -153.79Cr
Net Debt - -
Logo Sernova
Sernova Biotherapeutics Inc. is a Canada-based clinical-stage company, which is focused on developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem cell-derived cell therapies to create bio-hybrid organs to treat chronic diseases. A bio-hybrid organ is comprised of non-biomaterials, such as the Cell Pouch, integrated with living tissues to restore or enhance the function of a compromised organ. This approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on type 1 diabetes (T1D) and thyroid disorders. Cell Pouch is a bio-hybrid organ which is surgically implanted beneath the skin of the abdomen.
Employees
-
Date Price Change
02/26/02 CA$0.1050 -4.55%
01/26/01 CA$0.1100 +4.76%
30/26/30 CA$0.1050 +16.67%
29/26/29 CA$0.0900 0.00%
28/26/28 CA$0.0900 0.00%
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.1050CAD
Average target price
1.000CAD
Spread / Average Target
+852.38%

Quarterly revenue - Rate of surprise